Treatments received and transition rates through lines of therapy or death
| Landmark | 6 Months | 12 Months | 24 Months | |||
|---|---|---|---|---|---|---|
| BRCA/ATM Mutational Status | Yes | No | Yes | No | Yes | No |
| Number Treated | 203 | 221 | 237 | 253 | 264 | 282 |
| Received PARP Inhibitor (any line),% | 25.6 | 6.3 | 43.5 | 17.4 | 51.5 | 24.5 |
| Received Bevacizumab (any line),% | 14.8 | 17.2 | 21.1 | 29.6 | 25.4 | 34.4 |
| Transitions through lines of therapy,% | ||||||
| receiving/completed 2L treatment or died | 31.5 | 21.3 | 54.4 | 46.6 | 63.6 | 63.5 |
| receiving/completed 3L treatment or died | 4.9 | 5.0 | 23.2 | 15.0 | 39.8 | 32.6 |